Collaboration with Intel® for AI-powered medical screening optimizations

TAIPEI, March 31, 2025 /PRNewswire/ -- Acer Medical has recently launched its AI-assisted screening software, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration. These innovative solutions will be showcased at the Malaysian Ophthalmology Society (MSO) Annual Congress, bringing cutting-edge AI screening technology to Malaysia's ophthalmic community.

Acer Medical collaborates with Intel® to optimize AI-powered medical screening.

In collaboration with Intel, Acer Medical is advancing AI-driven medical imaging by accelerating AI inferencing and optimizing resource use with OpenVINO™ technology running on Intel® Core™ Ultra processors. OpenVINO™ is an open-source software toolkit designed for optimizing and deploying deep learning models. It significantly reduces development time by streamlining code implementation, facilitates rapid scalability, and enhances the efficiency of AI solutions. This collaboration ensures that advanced medical AI solutions can be deployed across all levels of medical institutions to process color retinal images in real-time, thereby making the solution more accessible while enhancing diagnostic efficiency and accuracy.

Rising Diabetes Prevalence and Aging Population in Malaysia Drive AI Ophthalmology Adoption

According to data from the Malaysian Medical Device Authority (MDA), Malaysia has one of the highest diabetes prevalence rates in Southeast Asia. Diabetes affects 18.3% of adults aged 18 and above, meaning approximately one in five Malaysians is diagnosed with the disease. With an aging population, the incidence of diabetic complications, including diabetic retinopathy, is expected to rise.

Additionally, Malaysia is transitioning into an aging society, with the proportion of individuals aged 65 and above projected to reach 15.3%* by 2040. Age-related macular degeneration has become a leading cause of vision impairment among the elderly, underscoring the urgent need for early detection and preventive ophthalmic care.

Acer Medical collaborates with hospitals and clinics in Malaysia to evaluate AI-driven medical solutions, enhancing diagnostic accuracy and efficiency. The VeriSee AI ophthalmic screening software analyzes color fundus images within seconds, providing high-accuracy detection of diabetic retinopathy and age-related macular degeneration. AI screening technology improves medical efficiency, enabling faster diagnoses at primary care facilities and ensuring timely treatment recommendations.

Intel® OpenVINO™ Enhances AI Performance and Accessibility in Clinical Settings

To ensure the seamless operation of AI medical solutions in clinical settings, Acer Medical has partnered with Intel to offer a trial program featuring the VeriSee series AI solutions with OpenVINO™ technology deployed on laptops powered by Intel® Core™ Ultra processors. This collaboration is being implemented in leading hospitals such as Universiti Malaysia Sabah Hospital (HUMS) and International Medical University (IMU) Hospital.

OpenVINO™ accelerates AI inference with lower latency and higher throughput while maintaining accuracy, allowing real-time image analysis for healthcare professionals, thereby improving decision-making accuracy. In this collaboration, it optimizes the VeriSee AI series workflow, including though processing and diagnostic efficiencies.

Expanding AI Healthcare Solutions Across Southeast Asia

Acer Medical's VeriSee AI solutions have been adopted by leading medical institutions globally and obtained regulatory certifications from Thailand, Indonesia and the Philippines. The company remains committed to improving AI-assisted medical solutions by collaborating with local healthcare institutions. In the coming years, Acer Medical aims to further deploy AI medical solutions, optimize medical resource allocation, and improve early disease detection capabilities through strategic collaborations and continuous innovation in AI healthcare technologies.

*Diabetes Medication Therapy Adherence Clinic Protocol from MOH Malaysia
https://pharmacy.moh.gov.my/sites/default/files/document-upload/dmtac-protocol-2022.pdf 

*Healthy Ageing in Malaysia by 2030: Needs, Challenges and Future Directions
https://pmc.ncbi.nlm.nih.gov/articles/PMC11376998/

Source: Acer Medical Inc.